DOCSLIB.ORG

Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table of Contents NTICANCER ESEARCH InternationalA Journal of Cancer ResearchR and Treatment ISSN: 0250-7005 Volume 24, Number 4, July-August 2004 Contents Experimental Studies Inhibition of the Human Apurinic/Apyrimidinic Endonuclease (Ape1) Repair Activity and Sensitization of Breast Cancer Cells to DNA Alkylating Agents with Lucanthone. M. LUO, M.R. KELLEY (Indianapolis, Indiana, USA)........................................................................................................................................................... 2127 Androgen Withdrawal Inhibits Tumor Growth and is Associated with Decrease in Angiogenesis and VEGF Expression in Androgen-Independent CWR22Rv1 Human Prostate Cancer Model. L. CHENG, S. ZHANG, C.J. SWEENEY, C. KAO, T.A GARDNER, J.N. EBLE (Indianapolis, Indiana, USA) .................................. 2135 In Vitro Generation of Cytolytic T Cells Against Human Melanoma Cells Overexpressing HDM2. A. SORURI, A. FAYYAZI, S. GANGL, C. GRIESINGER, C.A. ALBRECHT, T. SCHLOTT (Goettingen; Langen, Germany) .................................................................................................................................................... 2141 Artemisinin: An Alternative Treatment for Oral Squamous Cell Carcinoma. E. YAMACHIKA, T. HABTE, D. ODA (Seattle, WA, USA; Okayama City, Japan).............................................................................................. 2153 S19-mRNA Expression in Squamous Cell Carcinomas of the Upper Aerodigestive Tract. V. SENGPIEL, T. ROST, T. GÖRÖGH, I.O. RATHCKE, J.A. WERNER (Marburg; Kiel, Germany) ........................................ 2161 Three-dimensional Culture System as a Model for Studying Cancer Cell Invasion Capacity and Anticancer Drug Sensitivity. C.J. DOILLON, E. GAGNON, R. PARADIS, M. KOUTSILIERIS (Quebec, Canada; Athens, Greece)......................................................................................................................................................... 2169 Targeting Chemotherapy-induced VEGF Up-regulation by VEGF Antisense Oligonucleotides in HNSCC Cell Lines. F. RIEDEL, K. GÖTTE, U. GOESSLER, H. SADICK, K. HÖRMANN (Mannheim, Germany) ......................................................................................................................................................... 2179 Contents continued on the back cover Contents continued Cyclin D1 Expression in Endometrioid-type Endometrial Adenocarcinoma is Correlated with Histological Grade and Proliferative Activity, but not with Prognosis. Y. NISHIMURA, J. WATANABE, T. JOBO, N. KATO, T. FUJISAWA, Y. KAMATA, H. KURAMOTO (Kanagawa, Japan) ................................................. 2185 Low Renal Toxicity of Lipoplatin Compared to Cisplatin in Animals. P. DEVARAJAN, R. TARABISHI, J. MISHRA, Q. MA, A. KOURVETARIS, M. VOUGIOUKA, T. BOULIKAS (Cincinnati, OH; Mountain View, VA, USA; Athens, Greece).............................................................................................................................. 2193 TZT-1027 Elucidates Antitumor Activity through Direct Cytotoxicity and Selective Blockade of Blood Supply. N. HASHIGUCHI, T. KUBOTA, J.-I. KOH, Y. YAMADA, Y. SAIKAWA, Y. OTANI, M. WATANABE, K. KUMAI, M. KITAJIMA, J.-I. WATANABE, M. KOBAYASHI (Tokyo; Saitama; Kanagawa, Japan).......... 2201 Probucol, a Hypocholesterolemic Agent, Prevents the Development of Uterine Adenomyosis Induced by Pituitary Grafting in Mice. Y.-F. ZHOU, T. MORI, H. NAGASAWA, T. NAKAYAMA, T. KUBOTA, S. SAKAMOTO (Beijing, China; Chiba; Kanagawa; Tokyo, Japan) ........................................................................ 2209 Growth-inhibitory Effects of the Ketone Body, Monoacetoacetin, on Human Gastric Cancer Cells with Succinyl-CoA: 3-Oxoacid CoA-Transferase (SCOT) Deficiency. M. SAWAI, M. YASHIRO, Y. NISHIGUCHI, M. OHIRA, K. HIRAKAWA (Osaka, Japan)........................................................................... 2213 Clinical Relevance of HER-2/neu Expression in Germ-cell Testicular Tumors. L. MÁNDOKY, L. GÉCZI, I. BODROGI, J. TÓTH, O. CSUKA, M. KÁSLER, M. BAK (Budapest, Hungary) ......................................... 2219 Antineoplastic Effect of Immunostimulatory DNA (CpG-ODN) in a Murine C57-BL6 / MB-49 Transitional Cell Carcinoma Model. A. HEGELE, A. DALPKE, P. BARTH, Z. VARGA, K. HEEG, R. HOFMANN, P. OLBERT (Marburg, Germany)........................................................................................................................... 2225 Effective Knock Down of Very High ABCG2 Expression by a Hammerhead Ribozyme. P. KOWALSKI, K.M. FARLEY, H. LAGE, E. SCHNEIDER (Albany, NY, USA; Berlin, Germany) ........................................ 2231 Diffuse Growth Pattern Affects E-Cadherin Expression in Invasive Breast Cancer. U. BRINCK, S. JACOBS, M. NEUSS, K. TORY, W. RATH, B. KULLE, L. FÜZESI (Göttingen; Aachen, Germany) ......... 2237 * Involvement of Endothelial Monocyte Activating Polypeptide II in Tumor Necrosis Factor-alpha-based Anti-cancer Therapy. T.E. LANS, R. VAN HORSSEN, A.M.M. EGGERMONT, T.L.M. TEN HAGEN (Rotterdam, The Netherlands).................................................................................................................................. 2243 Chemoimmunotherapy of Murine Mammary Adenocarcinomas. I.H. AMES (Syracuse, NY, USA)............... 2249 Perivascular Mast Cells in Advanced Gastric Adenocarcinomas: An Electron Microscopic Study. R.A. CARUSO, A. IENI, V. FABIANO, G. BASILE, C. INFERRERA (Messina, Italy)........................................ 2257 Pre-clinical Immunogenicity and Anti-tumour Efficacy of a Deleted Recombinant Human Papillomavirus Type 16 E7 Protein. S. HALLEZ, J.-M. BRULET, C. VANDOOREN, F. MAUDOUX, S. THOMAS, M. HEINDERICKX, A. BOLLEN, R. WATTIEZ, A. JACQUET (Gosselies; Mons, Belgium)........................... 2265 Artemisinin Induces Apoptosis in Human Cancer Cells. N.P. SINGH, H.C. LAI (Seattle, WA, USA)........... 2277 Effects of the Polyacetylene Capillin on Human Tumour Cell Lines. L.C. WHELAN, M.F. RYAN (Dublin, Ireland)...................................................................................................................................................................... 2281 Involvement of Pattern Recognition Receptors in the Induction of Cytokines and Reactive Oxygen Intermediates Production by Human Monocytes/Macrophages Stimulated with Tumour Cells. B. MYTAR, M. WOLOSZYN, A. MACURA-BIEGUN, B. HAJTO, I. RUGGIERO, B. PIEKARSKA, M. ZEMBALA (Cracow; Poland)........ 2287 Isolated Limb Perfusion Based Anti-p21ras Gene Therapy in a Rat Rhabdomyosarcoma. B. VAN ETTEN, S.T. VAN TIEL, G. AMBAGTSHEER, A.M.M. EGGERMONT, T.L.M. TEN HAGEN (Rotterdam, The Netherlands)............................................................................................................................ 2295 Contents continued on the preceding page Contents continued Acoustic Energy: A New Transfection Method for Cancer of the Prostate, Cancer of the Bladder and Benign Kidney Cells. M.S. MICHEL, P. ERBEN, L. TROJAN, A. SCHAAF, K. KIKNAVELIDZE, T. KNOLL, P. ALKEN (Mannheim, Germany) .................................................................................................... 2303 Epstein-Barr Virus LMP1 Status in Relation to Apoptosis, P53 Expression and Leucocyte Infiltration in Nasopharyngeal Carcinoma. J.-Y. SHAO, I. ERNBERG, P. BIBERFELD, T. HEIDEN, Y.-X. ZENG, L.- F. HU (Stockholm, Sweden; Guangzhou, China)................................................................................................... 2309 Can Recurrence of Meningiomas be Predicted? J.-P. KALALA, D. BENOIT, L. DE RIDDER (Ghent, Belgium) .................................................................................................................................................................... 2319 Erythroid Differentiation in K562 Chronic Myelogenous Cells Induced by Crambescidin 800, a Pentacyclic Guanidine Alkaloid. S. AOKI, D. KONG, K. MATSUI, M. KOBAYASHI (Osaka, Japan)........................... 2325 Somatostatin Controls LFA-1 Gene Expression by Altering Neuraminidase Expression in Spleen Cells. W.- K. YOON, H.-J. KIM, H.-Y. SON, K.-S. JEONG, S.-J. PARK, T.-H. KIM, S.-H. KIM, S.-R. KIM, S.-Y. RYU (Daejon; Daegu; Kwangju, South Korea) ...................................................................................................... 2331 Amifostine Protects Against Chemotherapy-induced Neurotoxicity: An In Vitro Investigation. C.C.P. VERSTAPPEN, T.J. POSTMA, A.A. GELDOF, J.J. HEIMANS (Amsterdam, The Netherlands) ................. 2337 Antitumour Effectiveness of Hyperthermia is Potentiated by Local Application of Electric Pulses to LPB Tumours in Mice. K.B. KARNER, H. LESNICAR, M. CEMAZAR, G. SERSA (Ljubljana, Slovenia)........ 2343 Elevated Cyclooxygenase-2 Expression Correlates with Distant Metastases in Breast Cancer. G.S. RANGER, V. THOMAS, A. JEWELL, K. MOKBEL (London, UK) ............................................................... 2349 Changes in Serum Soluble VEGFR-1 and Tie-2 Receptors in Colorectal Cancer Patients Following Surgical Resections. K.-F. CHIN, J. GREENMAN, P. REUSCH, E. GARDINER, D. MARME, J. MONSON (Hull, UK; Freiburg, Germany) .......................................................................................................................................... 2353 Clinical Studies Correlation of FDG-PET Interpretation with Survival in a Cohort of Glioma Patients. F.S. PARDO, H.J. ARONEN, M. FITZEK, D.N. KENNEDY, J. EFIRD, B.R. ROSEN,
Load more

Recommended publications
  • Restoration of Temozolomide Sensitivity by PARP Inhibitors In
    Published OnlineFirst January 3, 2020; DOI: 10.1158/1078-0432.CCR-19-2000 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair Fumi Higuchi1,2, Hiroaki Nagashima1, Jianfang Ning1,3, Mara V.A. Koerner1, Hiroaki Wakimoto1, and Daniel P. Cahill1 ABSTRACT ◥ Purpose: Emergence of mismatch repair (MMR) deficiency is a Results: While having no detectable effect in MSH6 wild-type frequent mechanism of acquired resistance to the alkylating che- GBMs, PARPi selectively restored TMZ sensitivity in MSH6- motherapeutic temozolomide (TMZ) in gliomas. Poly(ADP-ribose) deficient GBM cells. This genotype-specific restoration of activity polymerase inhibitors (PARPi) have been shown to potentiate TMZ translated in vivo, where combination treatment of veliparib cytotoxicity in several cancer types, including gliomas. We tested and TMZ showed potent suppression of tumor growth of whether PARP inhibition could re-sensitize MSH6-null MMR- MSH6-inactivated orthotopic xenografts, compared with TMZ deficient gliomas to TMZ, and assessed the role of the base excision monotherapy. Unlike PARPi, genetic and pharmacological block- repair (BER) DNA damage repair pathway in PARPi-mediated age of BER pathway did not re-sensitize MSH6-inactivated GBM effects. cells to TMZ. Similarly, CRISPR PARP1 knockout did not re- Methods: Isogenic pairs of MSH6 wild-type and MSH6-inacti- sensitize MSH6-inactivated GBM cells to TMZ. vated human glioblastoma (GBM) cells (including both IDH1/2 Conclusions: PARPi restoration of TMZ chemosensitivity in wild-type and IDH1 mutant), as well as MSH6-null cells derived MSH6-inactivated glioma represents a promising strategy to from a patient with recurrent GBM were treated with TMZ, the overcome acquired chemoresistance caused by MMR deficiency.
    [Show full text]
  • Induction of Concentration-Dependent Blockade in the G2 Phase of the Cell Cycle by Cancer Chemotherapeutic Agents1
    [CANCER RESEARCH 38, 809-814, March 1978] Induction of Concentration-dependent Blockade in the G2 Phase of the Cell Cycle by Cancer Chemotherapeutic Agents1 Bruce F. Kimler,2 Martin H. Schneiderman,3 and Dennis B. Leeper Laboratory of Experimental Radiation Oncology, Department of Radiation Therapy and Nuclear Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania ABSTRACT for detailed analysis. Thus, results have been limited to describing the location of a block in terms of general The mitotic cell selection procedure for cell cycle anal phases of the cell cycle, i.e., G,, S, G,,, M, or at the ysis was utilized with Chinese hamster ovary fibroblasts boundary between 2 phases. Even when greater precision to determine the transition points in G,, i.e., the age in G, was attained, seldom was a concentration dependence of at which cells become refractory to drug-induced progres the location of the block observed (29). sion blockade, for several cancer Chemotherapeutic Using the mitotic cell selection procedure for cell cycle agents and antimetabolites over a 1000-fold concentration analysis (26), we have determined the number of cells range. refractory to drug-induced G-,blockade after treatment with The G transition points for five anticancer drugs (acti- various concentrations of several cancer Chemotherapeutic nomycin D, Adriamycin, lucanthone, mitomycin C, and agents and antimetabolites. We were able to calculate the bleomycin) varied linearly as a function of the logarithm time in G2 at which a particular concentration of drug of the drug concentration between the S-G_,boundary at inhibited progression or induced a delay. low concentrations and prometaphase (45 min prior to the end of karyokinesis) at high concentrations.
    [Show full text]
  • WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/061161 A2 2 May 2013 (02.05.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/337 (2006.01) A61K 31/48 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/395 (2006.01) A61K 31/51 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/4174 (2006.01) A61K 31/549 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, A61K 31/428 (2006.01) A61K 31/663 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (21) International Application Number: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, PCT/IB20 12/002768 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (22) International Filing Date: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, 25 October 2012 (25.10.2012) RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (25) Filing Language: English ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/552,922 28 October 201 1 (28.
    [Show full text]
  • Predicting Potential Drugs for Breast Cancer Based on Mirna and Tissue Specificity
    Int. J. Biol. Sci. 2018, Vol. 14 971 Ivyspring International Publisher International Journal of Biological Sciences 2018; 14(8): 971-982. doi: 10.7150/ijbs.23350 Research Paper Predicting Potential Drugs for Breast Cancer based on miRNA and Tissue Specificity Liang Yu, Jin Zhao and Lin Gao School of Computer Science and Technology, Xidian University, Xi'an, 710071, P.R. China. Corresponding author: [email protected] © Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2017.10.16; Accepted: 2017.12.14; Published: 2018.05.22 Abstract Network-based computational method, with the emphasis on biomolecular interactions and biological data integration, has succeeded in drug development and created new directions, such as drug repositioning and drug combination. Drug repositioning, that is finding new uses for existing drugs to treat more patients, offers time, cost and efficiency benefits in drug development, especially when in silico techniques are used. MicroRNAs (miRNAs) play important roles in multiple biological processes and have attracted much scientific attention recently. Moreover, cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs. At the same time, human diseases result from the disordered interplay of tissue- and cell lineage-specific processes. However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity. Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity
    pharmaceuticals Article Quinolizidine-Derived Lucanthone and Amitriptyline Analogues Endowed with Potent Antileishmanial Activity Michele Tonelli 1,* , Anna Sparatore 2,* , Nicoletta Basilico 3,* , Loredana Cavicchini 3, Silvia Parapini 4 , Bruno Tasso 1 , Erik Laurini 5 , Sabrina Pricl 5,6 , Vito Boido 1 and Fabio Sparatore 1 1 Dipartimento di Farmacia, Università degli Studi di Genova, Viale Benedetto XV, 3, 16132 Genova, Italy; [email protected] (B.T.); [email protected] (V.B.); [email protected] (F.S.) 2 Dipartimento di Scienze Farmaceutiche, Università degli Studi di Milano, Via Mangiagalli 25, 20133 Milano, Italy 3 Dipartimento di Scienze Biomediche Chirurgiche e Odontoiatriche, Università degli Studi di Milano, Via Pascal 36, 20133 Milano, Italy; [email protected] 4 Dipartimento di Scienze Biomediche per la Salute, Università degli Studi di Milano, Via Mangiagalli 31, 20133 Milano, Italy; [email protected] 5 Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), DEA, Piazzale Europa 1, 34127 Trieste, Italy; [email protected] (E.L.); [email protected] (S.P.) 6 Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland * Correspondence: [email protected] (M.T.); [email protected] (A.S.); [email protected] (N.B.) Received: 4 October 2020; Accepted: 21 October 2020; Published: 25 October 2020 Abstract: Leishmaniases are neglected diseases that are endemic in many tropical and sub-tropical Countries. Therapy is based on different classes of drugs which are burdened by severe side effects, occurrence of resistance and high costs, thereby creating the need for more efficacious, safer and inexpensive drugs.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Versitat Munster. the Production of Single Strand Breaks
    ABSTRACTS OF PROFFERED PAPERS 757 WuBKER, Institut fiir Strahlenbiologie, Uni­ experiment (3Fj4D) was studied. Bleomycin versitat Munster. was found to apparently decrease, by about The production of single strand breaks 30%, the repair of sublethal radiation (SSBs) and double strand breaks (DSBs) in damage when given simultaneously with the T 2 DNA (16 ttgfml) by bleomycin (Bl) radiation exposure (5 mgfkg). (40 ttgfml) was investigated quantitatively. At 5°C 0·11 SSBjmin per T 2 genom were found. The addition of 1 mmol cysteamine RADIATION AND ANTI-TUMOUR (SH) enhances the single strand breakage rate DRUGS. M. BARKER-GRIMSHAW, K. HELL­ by a factor of 25. DSBs were found at a rate MANN and G. E. MuRKIN, Chemotherapy of 0·5/min only in the presence of SH and Bl. Department, Imperial Cancer Research Fund, Since the accidental DSB rate due to SSBs in London. opposite DNA strands is less than I0- 3jmin Growth inhibitory effects of the anti­ per T 2 genom DSBs must be produced tumour drugs 5-fl.ourouracil, adriamycin, directly by the action of Bl. The obtained hydroxyurea, bleomycin, cyclophosphamide, DNA profiles did not follow a random methotrexate, ICRF 159 and 593A and the distribution; thus bleomycin apparently acts radiosensitizer Ro-07-0582 combined with a at specific sites along the T 2 genom. X­ standard dose of radiation was tested on the irradiation followed by Bl-SH treatment radiosensitive sarcoma 180. The most effec­ resulted in an increased DNA degradation. tive potentiators were 593A and ICRF 159. The number of SSBs is at least 3 times larger They were then examined against the than expected if the effect of both treatments relatively radioresistant Lewis lung carcinoma is just additive.
    [Show full text]
  • 2014 Annual Report
    SPECTRUM PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 03/13/15 for the Period Ending 12/31/14 Address 11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052 Telephone 702-835-6300 CIK 0000831547 Symbol SPPI SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2015, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 93-0979187 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 11500 South Eastern Avenue, Suite 240 Henderson, Nevada 89052 (Address of principal executive offices) (702) 835-6300 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $0.001 par value The NASDAQ Stock Market, LLC Rights to Purchase Series B Junior Participating Preferred Stock Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Protocol Update #09 ALLIANCE for CLINICAL TRIALS in ONCOLOGY
    Protocol Update #09 ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY _________________________________________ PROTOCOL UPDATE TO ALLIANCE A071102 _________________________________________ A PHASE II/III RANDOMIZED TRIAL OF VELIPARIB OR PLACEBO IN COMBINATION WITH ADJUVANT TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA WITH MGMT PROMOTER HYPERMETHYLATION Investigational Agent: veliparib (NSC #737664) will be supplied by NCI DCTD - CTEP IND Commercial agent(s): temozolomide Imaging site credentialing required for participation ClinicalTrials.gov Identifier: NCT02152982 X Update: Status Change: Eligibility changes Activation Therapy / Dose Modifications / Study Calendar changes Closure Informed Consent changes Suspension / temporary closure X Scientific / Statistical Considerations changes Reactivation Data Submission / Forms changes X Editorial / Administrative changes Other : If your site utilizes the CIRB as your IRB of record No recommended IRB level of review is provided by the Alliance since the CIRB is the IRB of record for this trial. The site has 30 days after the posting of this amendment to implement it at their site. Please refer to the amendment application and CIRB guidelines for further instructions. If your site utilizes a local IRB as your IRB of record IRB approval (or disapproval) is required within 90 days. Please follow your local IRB guidelines. Expedited review is allowed. IRB approval (or disapproval) is required within 90 days. Please follow your IRB of record guidelines. UPDATES TO THE PROTOCOL 1 Cover Page Lilli Johnson has replaced Sakuni Taniya Silva as the Protocol Coordinator, and all contact information has been updated. Protocol Contacts (page 2) • Lori Cappello has replaced Wanda L. DeKrey as the A071102 Nursing Contact, and all contact information has been updated. • The IROC contact information has been updated Cancer Trials Support Unit Address and Contact Information (page 3) The CTSU Contact Information table has been updated with current CTSU logistical common language.
    [Show full text]
  • Predicting Potential Treatments for Complex Diseases Based on Mirna and Tissue Specificity
    Predicting potential treatments for complex diseases based on miRNA and tissue specificity Liang Yu* School of Computer Science and Technology, Xidian University, Xi'an, 710071, P.R.China [email protected] *Corresponding author Jin Zhao School of Computer Science and Technology, Xidian University, Xi'an, 710071, P.R.China [email protected] Lin Gao School of Computer Science and Technology, Xidian University, Xi'an, 710071, P.R.China [email protected] Abstract Network-based computational method, with the emphasis on biomolecular interactions and biological data integration, has succeeded in drug development and created new directions, such as drug repositioning and drug combination. Drug repositioning, that is finding new uses for existing drugs to treat more patients, offers time, cost and efficiency benefits in drug development, especially when in silico techniques are used. microRNAs (miRNAs) play important roles in multiple biological processes and have attracted much scientific attention recently. Moreover, cumulative studies demonstrate that the mature miRNAs as well as their precursors can be targeted by small molecular drugs. At the same time, human diseases result from the disordered interplay of tissue- and cell lineage-specific processes. However, few computational researches predict drug-disease potential relationships based on miRNA data and tissue specificity. Therefore, based on miRNA data and the tissue specificity of diseases, we propose a new method named as miTS to predict the potential treatments for diseases. Firstly, based on miRNAs data, target genes and information of FDA (Food and Drug Administration) approved drugs, we evaluate the relationships between miRNAs and drugs in the tissue-specific PPI (protein-protein) network.
    [Show full text]
  • Polymerase Inhibitors in Mismatch Repair Deficient Glioblastoma Is Independent of Base Excision
    Author Manuscript Published OnlineFirst on January 3, 2020; DOI: 10.1158/1078-0432.CCR-19-2000 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Title: Restoration of Temozolomide Sensitivity by Poly(ADP-Ribose) Polymerase inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair Authors: Fumi Higuchi1, 2, Hiroaki Nagashima1, Jianfang Ning1, 3, Mara V.A. Koerner1, Hiroaki Wakimoto*1 and Daniel P. Cahill*1 Affiliations:1 Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114 2Department of Neurosurgery, Dokkyo Medical University, Mibu, Tochigi, Japan 3 Department of Neurosurgery, University of Minnesota Medical School, Minneapolis, MN Running title: MMR-deficient GBM re-sensitized to TMZ by PARP inhibitors. Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 3, 2020; DOI: 10.1158/1078-0432.CCR-19-2000 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Keywords: Glioma, temozolomide, PARP inhibitor, Mismatch Repair, Base excision repair Financial Support: Burroughs Wellcome Fund Career Award (D. Cahill), NIH R01CA227821 (D. Cahill and H. Wakimoto), P50CA165962 (D. Cahill), Tawingo fund (D. Cahill), Loglio fund (D. Cahill), OligoNation fund (D. Cahill). Corresponding Authors: *Daniel P. Cahill, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114. Phone: 617-724-1191; Fax: 617-724-8769; Email: [email protected]. *Hiroaki Wakimoto, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA, 02114. Phone: 617-724-1191; Fax: 617-724-8769; Email: ([email protected]) Conflicts of Interest: All authors have no conflicts of interest to report with regard to this manuscript.
    [Show full text]